Share price
-5.56%
Turnover
0.88 MSEK
Calendar
| Est. time* | ||
| 2026-02-25 | 08:20 | Year-end Report 2025 |
| 2025-11-06 | 08:30 | Quarterly Report 2025-Q3 |
| 2025-08-13 | - | Quarterly Report 2025-Q2 |
| 2025-06-26 | - | Annual General meeting |
| 2025-05-28 | - | Quarterly Report 2025-Q1 |
| 2025-05-21 | - | Ex-date Ordinary Dividend PMED 0.00 SEK |
| 2025-02-28 | - | Year-end Report 2024 |
| 2025-01-07 | - | Extra General Meeting 2024 |
| 2024-11-06 | - | Quarterly Report 2024-Q3 |
| 2024-08-15 | - | Quarterly Report 2024-Q2 |
| 2024-05-22 | - | Ex-date Ordinary Dividend PMED 0.00 SEK |
| 2024-05-21 | - | Annual General meeting |
| 2024-05-07 | - | Quarterly Report 2024-Q1 |
| 2024-02-23 | - | Year-end Report 2023 |
| 2024-01-11 | - | Extra General Meeting 2023 |
| 2023-10-24 | - | Quarterly Report 2023-Q3 |
| 2023-08-11 | - | Quarterly Report 2023-Q2 |
| 2023-04-24 | - | Quarterly Report 2023-Q1 |
| 2023-04-21 | - | Ex-date Ordinary Dividend PMED 0.00 SEK |
| 2023-04-20 | - | Annual General meeting |
| 2023-02-24 | - | Year-end Report 2022 |
| 2023-01-09 | - | Extra General Meeting 2022 |
| 2022-11-10 | - | Quarterly Report 2022-Q3 |
| 2022-08-18 | - | Quarterly Report 2022-Q2 |
| 2022-05-25 | - | Ex-date Ordinary Dividend PMED 0.00 SEK |
| 2022-05-24 | - | Annual General meeting |
| 2022-05-12 | - | Quarterly Report 2022-Q1 |
| 2022-02-25 | - | Year-end Report 2021 |
| 2021-12-16 | - | Extra General Meeting 2021 |
| 2021-11-10 | - | Quarterly Report 2021-Q3 |
| 2021-08-18 | - | Quarterly Report 2021-Q2 |
| 2021-06-10 | - | Ex-date Ordinary Dividend PMED 0.00 SEK |
| 2021-05-27 | - | Annual General meeting |
| 2021-05-12 | - | Quarterly Report 2021-Q1 |
| 2021-02-26 | - | Year-end Report 2020 |
| 2020-11-10 | - | Quarterly Report 2020-Q3 |
| 2020-08-17 | - | Quarterly Report 2020-Q2 |
| 2020-07-28 | - | Extra General Meeting 2020 |
| 2020-06-30 | - | Annual General meeting |
| 2020-06-17 | - | Ex-date Ordinary Dividend PMED 0.00 SEK |
| 2020-05-14 | - | Quarterly Report 2020-Q1 |
| 2020-02-27 | - | Year-end Report 2019 |
| 2019-11-08 | - | Quarterly Report 2019-Q3 |
| 2019-08-16 | - | Quarterly Report 2019-Q2 |
| 2019-06-20 | - | Ex-date Ordinary Dividend PMED 0.00 SEK |
| 2019-06-19 | - | Annual General meeting |
| 2019-05-15 | - | Quarterly Report 2019-Q1 |
| 2019-02-27 | - | Year-end Report 2018 |
| 2018-11-09 | - | Quarterly Report 2018-Q3 |
| 2018-08-17 | - | Quarterly Report 2018-Q2 |
| 2018-05-15 | - | Quarterly Report 2018-Q1 |
| 2018-03-29 | - | Ex-date Ordinary Dividend PMED 0.00 SEK |
| 2018-03-28 | - | Annual General meeting |
| 2018-02-27 | - | Year-end Report 2017 |
| 2017-11-09 | - | Quarterly Report 2017-Q3 |
| 2017-08-17 | - | Quarterly Report 2017-Q2 |
| 2017-05-19 | - | Ex-date Ordinary Dividend PMED 0.00 SEK |
| 2017-05-18 | - | Annual General meeting |
| 2017-05-16 | - | Quarterly Report 2017-Q1 |
| 2017-02-27 | - | Year-end Report 2016 |
| 2016-11-10 | - | Quarterly Report 2016-Q3 |
| 2016-08-17 | - | Quarterly Report 2016-Q2 |
| 2016-07-22 | - | Extra General Meeting 2016 |
| 2016-05-20 | - | Ex-date Ordinary Dividend PMED 0.00 SEK |
| 2016-05-19 | - | Annual General meeting |
| 2016-05-17 | - | Quarterly Report 2016-Q1 |
| 2016-02-26 | - | Year-end Report 2015 |
| 2015-11-19 | - | Extra General Meeting 2015 |
| 2015-11-11 | - | Quarterly Report 2015-Q3 |
| 2015-08-17 | - | Quarterly Report 2015-Q2 |
| 2015-05-08 | - | Quarterly Report 2015-Q1 |
| 2015-04-10 | - | Ex-date Ordinary Dividend PMED 0.00 SEK |
| 2015-04-09 | - | Annual General meeting |
| 2015-02-27 | - | Year-end Report 2014 |
| 2014-10-15 | - | Quarterly Report 2014-Q3 |
| 2014-08-13 | - | Quarterly Report 2014-Q2 |
Description
| Country | Sweden |
|---|---|
| List | Spotlight |
| Sector | Health care |
| Industry | Biotechnology |
The Board of Directors of Peptonic Medical AB (publ.) ("Peptonic" or the "Company") has decided to postpone the publication of its interim report for the first quarter of 2025. The interim report will be published on May 28, 2025, instead of the previously communicated date of May 7, 2025.
The reason is that the Company needs additional time to complete the report, taking into account the ongoing corporate restructuring. Peptonic is working purposefully to strengthen the company's financial position. The interim report will provide an update on developments during the period, including progress in the restructuring and measures implemented to create a long-term sustainable and profitable business. The company is also postponing the Annual General Meeting and Annual report for the same reason. The new date for the Annual General Meeting will be June 26, 2025 and the Annual report will be published no later than June 5, 2025.
For more information contact:
Anna Linton, CEO Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About PEPTONIC medical AB
PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.
The Company is headquartered in Stockholm, Sweden, and operate the subsidiaries Peptonic medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.